Janus Kinase Inhibitors Promising for Difficult-to-Treat RA
Tofacitinib Promising for COVID-19 Pneumonia
Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks
Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More
Late-Breaking Abstract Session Spans the Realm of Drug-Related Research
FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA
Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments
Researchers Give Update on Janus Kinase (JAK) Inhibitors
Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib
- 1
- 2
- 3
- …
- 5
- Next Page »